Top Markets
Coin of the day
PT Itama Ranoraya Tbk PT Itama Ranoraya Tbk

PT Itama Ranoraya Tbk

IRRA
Rank in Stocks #27331
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical... PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical products; and hospital supplies. It also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, the company leases office space. It sells its products under the oneject, Abbott, Terumo, Medtronic, HMD, BD, Vestfrost, Hemocue, Planmed, Sinmed, Balmed, Zepa, KSM CARE, Trisan Care, GEA, Hologic, IS, Avimac, RadmediX, MTS, and SMAM brands. PT Itama Ranoraya Tbk was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk is a subsidiary of PT Global Dinamika Kencana.
Share Price
$0.02222751
Market Cap
$33.52M
Change (1 day)
0.54%
Change (1 year)
-16.22%
Country
ID
Trade PT Itama Ranoraya Tbk (IRRA)

Category

Revenue for PT Itama Ranoraya Tbk (IRRA)
Revenue in Aug 2026 TTM: 0
According to PT Itama Ranoraya Tbk latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PT Itama Ranoraya Tbk from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$410.98B -
US
- -
US
$254.25B -
US
- -
US
$3.67B -
AU